Wilcox et al. (2022) show that NMDA receptor channel blockers, some of which are clinically important drugs, can access their binding site via 2 routes: a well-known path from the extracellular solution, and another path through the plasma membrane.
- Madeleine R. Wilcox
- Aparna Nigam
- Jon W. Johnson
